Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Current Assets (2016 - 2026)

Lexaria Bioscience's Current Assets history spans 12 years, with the latest figure at $5.8 million for Q1 2026.

  • Quarterly results put Current Assets at $5.8 million for Q1 2026, down 25.3% from a year ago — trailing twelve months through Feb 2026 was $5.8 million (down 25.3% YoY), and the annual figure for FY2025 was $3.5 million, down 56.09%.
  • Current Assets for Q1 2026 was $5.8 million at Lexaria Bioscience, up from $5.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $10.6 million in Q1 2022 to a low of $2.2 million in Q3 2023.
  • The 5-year median for Current Assets is $5.8 million (2026), against an average of $6.1 million.
  • The sharpest move saw Current Assets plummeted 69.17% in 2023, then skyrocketed 267.14% in 2024.
  • Year by year, Current Assets stood at $5.4 million in 2022, then plummeted by 49.74% to $2.7 million in 2023, then soared by 227.65% to $8.8 million in 2024, then tumbled by 39.23% to $5.4 million in 2025, then grew by 7.59% to $5.8 million in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $5.8 million, $5.4 million, and $3.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.